INM004

DB17791InvestigationalProtein Based Therapies

INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic uremic syndrome.

Mechanism: Pharmacologically active on Shiga-like toxin 1 subunit B and Orf protein
Curator reviewed
Also known as: Anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment · Neutralizing equine anti-Stx hyperimmune immunoglobulin F(ab')2 fragment
Code names: INM004

Resolves to

Targets

P69178stxBQ47644stx2e B

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with INM004, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account